A late-stage trial of Eli Lilly’s weight loss drug Zepbound showed promising results in treating sleep apnea symptoms in ...
A new clinical trial from drugmaker Eli Lilly shows that Zepbound and Mounjaro reduced obstructive sleep apnea symptoms.
The U.S. Food and Drug Administration (FDA) approved Zepbound for the treatment of obesity in November 2023. Some prescribe ...
The weight-loss drug Zepbound was linked to a reduction in obstructive sleep apnea (OSA), according to new research.
Eli Lilly announced today that the drug behind Zepbound was found to help alleviate sleep apnea in patients with obesity in ...
Zepbound, one of the wildly popular weight-loss drugs that millions of Americans now take, eased sleep apnea in obese adults ...
Eli Lilly and Company announced promising results for its weight loss drug Zepbound, indicating its potential as a treatment ...
Drugmaker Eli Lilly said Wednesday its weight loss drug Zepbound was shown to “significantly reduce” sleep apnea severity in adults in clinical trials.
The results, while unpublished, are the latest in a string of hopeful signs for weight loss drugs to treat a variety of conditions.
Weight loss drugs like Ozempic and Mounjaro have gained great traction in recent months, and now drugmakers have found ...
In a new study, people with obesity who received weight-loss drug Zepbound saw a greater average reduction in sleep apnea ...
Eli Lilly’s weight loss drug Zepbound was found to reduce obstructive sleep apnea in adults with obesity, the drugmaker said ...